Albireo patents expiration
1. Bylvay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(1 year, 7 months ago) | |
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(7 years from now) | |
| US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US11732006 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| US11801226 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11802115 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11583539 | ALBIREO | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
| New Indication(I-918) | Jun 13, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating cholestatic pruritus in patients 12 months or older suffering from alagille syndrome (algs); Method of reducing serum bile acids in patients 12 months or older suffering from alagil...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
More Information on Dosage
BYLVAY family patents
